Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyFri, 24 May 2024 20:08:27 +0200Wed, 10 Apr 2024 11:48:00 +0200Gavreto : EPAR - Product Informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5413-en_1.pdfGavreto : EPAR - Product Informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5413-en_1.pdfWed, 10 Apr 2024 11:48:00 +0200Human medicineHuman medicines European public assessment report (EPAR): Gavreto, pralsetinib, Date of authorisation: 18/11/2021, Revision: 7, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/gavretoHuman medicines European public assessment report (EPAR): Gavreto, pralsetinib, Date of authorisation: 18/11/2021, Revision: 7, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/gavretoWed, 10 Apr 2024 11:33:00 +0200Human medicine